Document Detail

Antithrombotic therapy for heart failure in sinus rhythm.
MedLine Citation:
PMID:  19735305     Owner:  NLM     Status:  MEDLINE    
Although the risk of thromboembolism in chronic heart failure is high even in the absence of atrial fibrillation, the risk to benefit ratio of anticoagulation vs. antiplatelet therapy or no antithrombotic therapy is poorly defined in this population. Post hoc analysis of large therapeutic heart failure trials has estimated the risk of thromboembolism to be between 1 and 4.5%. However, most of these studies have included some patients with atrial fibrillation, and thromboembolism was not a predefined endpoint. At present, the evidence for either anticoagulation or antiplatelet therapy is limited and the results from current large-scale randomized studies are awaited. From the randomized studies carried out thus far, there is a beneficial trend in favour of anticoagulation therapy, with less hospitalization for heart failure compared with patients taking aspirin.
Veeran Subramaniam; Russell C Davis; Eduard Shantsila; Gregory Y H Lip
Related Documents :
18317045 - New british and american guidelines for the antibiotic prophylaxis of infective endocar...
11872915 - Emergent use of anticoagulation for treatment of patients with ischemic stroke.
8996255 - Medical issues and emergencies in the dermatology office.
15692605 - Acute myocardial infarction in sickle cell disease: a possible complication of hydroxyu...
20932935 - Transgenic overexpression of hsp56 does not result in cardiac hypertrophy nor protect f...
16046825 - Cardiovascular damage in alzheimer disease: autopsy findings from the bryan adrc.
Publication Detail:
Type:  Journal Article; Review     Date:  2009-09-04
Journal Detail:
Title:  Fundamental & clinical pharmacology     Volume:  23     ISSN:  1472-8206     ISO Abbreviation:  Fundam Clin Pharmacol     Publication Date:  2009 Dec 
Date Detail:
Created Date:  2009-11-17     Completed Date:  2010-02-04     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8710411     Medline TA:  Fundam Clin Pharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  705-17     Citation Subset:  IM    
Haemostasis Thrombosis and Vascular Biology Unit, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / pharmacology,  therapeutic use*
Atrial Fibrillation / complications,  drug therapy
Chronic Disease
Fibrinolytic Agents / pharmacology,  therapeutic use*
Heart Failure / complications,  drug therapy*,  physiopathology
Platelet Aggregation Inhibitors / pharmacology,  therapeutic use*
Randomized Controlled Trials as Topic
Risk Factors
Sinoatrial Node / drug effects*,  physiopathology
Thromboembolism / etiology,  prevention & control
Reg. No./Substance:
0/Anticoagulants; 0/Fibrinolytic Agents; 0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The effect of nitroglycerin tolerance on oxidative stress and anaerobic sulfur metabolism in rat tis...
Next Document:  Evaluation of various gentamicin dosage regimens in geriatric patients: a simulation study.